258 related articles for article (PubMed ID: 16863690)
1. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
Van Gaal LF
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome and mental illness.
Newcomer JW
Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
[TBL] [Abstract][Full Text] [Related]
5. Schizophrenia and comorbid metabolic disorders.
Henderson DC
J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic medications: metabolic and cardiovascular risk.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
[TBL] [Abstract][Full Text] [Related]
7. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
8. Metabolic risk during antipsychotic treatment.
Newcomer JW
Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
[TBL] [Abstract][Full Text] [Related]
10. Metabolism, lifestyle and bipolar affective disorder.
Morriss R; Mohammed FA
J Psychopharmacol; 2005 Nov; 19(6 Suppl):94-101. PubMed ID: 16280342
[TBL] [Abstract][Full Text] [Related]
11. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Rzewuska M
Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
[TBL] [Abstract][Full Text] [Related]
12. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
13. The role of lifestyle interventions and weight management in schizophrenia.
Bushe C; Haddad P; Peveler R; Pendlebury J
J Psychopharmacol; 2005 Nov; 19(6 Suppl):28-35. PubMed ID: 16280335
[TBL] [Abstract][Full Text] [Related]
14. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
Monteleone P; Martiadis V; Maj M
Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics].
Cordes J; Sinha-Röder A; Kahl KG; Malevani J; Thuenker J; Lange-Asschenfeldt C; Hauner H; Agelink MW; Klimke A
Fortschr Neurol Psychiatr; 2008 Dec; 76(12):703-14. PubMed ID: 18924059
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome and cardiovascular disease.
Citrome L
J Psychopharmacol; 2005 Nov; 19(6 Suppl):84-93. PubMed ID: 16280341
[TBL] [Abstract][Full Text] [Related]
17. Mortality in schizophrenia.
Auquier P; Lançon C; Rouillon F; Lader M
Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1308-12. PubMed ID: 17944000
[TBL] [Abstract][Full Text] [Related]
18. Risk of cardiovascular disease and sudden death in schizophrenia.
Davidson M
J Clin Psychiatry; 2002; 63 Suppl 9():5-11. PubMed ID: 12088174
[TBL] [Abstract][Full Text] [Related]
19. Effects of atypical antipsychotics on weight and serum lipid levels.
Meyer JM
J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
[TBL] [Abstract][Full Text] [Related]
20. Schizophrenia and obesity: impact of antipsychotic medications.
Wirshing DA
J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
